Additionally, I predict that at the completion
of our
study, despite the higher doses given per treatment in the
experimental accelerated, hypofractionated RT
arm, there will be no increased toxicity with this regimen.
Specifically, Delfraissy says if the monkey
studies and the finer analysis
of patient samples have positive results, perhaps the standard
of care should include favipiravir as part
of the control
arm in
studies of ZMapp and other
experimental treatments.